Key Secondary
: This is the label prefix. It identifies the "S-One" brand. Other labels use different prefixes (e.g., SNIS , SSNI , IPX ). SONE-040
Unlike many drugs that target a single pathway, SONE-040 is built as a . It typically combines two potent immune-stimulating cytokines—such as IL-12 and IL-15 —into a single molecule. IL-12 helps "turn cold tumors hot" by recruiting T-cells. Key Secondary : This is the label prefix
If SONE-040 shows meaningful clinical benefit, predictable biomarker correlates, and a favorable safety profile, it could offer a new oral option for moderate-to-severe AD with opportunities for precision use guided by molecular signatures — addressing both symptomatic relief and mechanistic understanding. predictable biomarker correlates